Treatment of Major Depression

Major depression is a debilitating psychiatric condition in which the brain's chemical signaling goes persistently awry, and pharmacological research aims to understand precisely which molecular targets can reliably restore it. Classical antidepressants work primarily on serotonin and norepinephrine systems, but their slow onset and frequent failures in treatment-resistant patients have pushed researchers toward glutamate signaling, particularly the NMDA receptor, which ketamine blocks with striking and rapid effect. A central open question is how to capture ketamine's fast-acting benefits without its dissociative side effects and potential for misuse, while a related challenge is disentangling the cognitive impairments that depression itself causes from those introduced by the drugs meant to treat it. Understanding the synaptic plasticity changes that underlie both the illness and its remission remains an active frontier, with the hope of guiding more targeted therapies for the substantial portion of patients whom current treatments leave behind.

Works

63,243

Total citations

1,386,312

Keywords

DepressionAntidepressantKetamineNMDA ReceptorTreatment-Resistant DepressionNeurobiological Mechanisms